

Lonza Ltd Muenchensteinerstrasse 38 CH-4002 Basel, Switzerland +41 61 316 81 11 +41 61 316 91 11 media@lonza.com



News Release

Lonza to Increase and Expand Capabilities for Drug Product Services for Parenteral Dosage Forms

- Operational since November 2016, Drug Product Services will expand their facility in Basel (CH) and increase capacity for existing services including: Formulation Development, Drug Product Analytics & QC, and Special Services
- Expansion includes new capability for Drug Product Process Development
- Together with Capsugel's expertise in Oral Solids, Lonza now provides high-end solutions for both Oral and Parenteral Dosage Forms

Basel, Switzerland, 24 August 2017 – Lonza announced today that its Pharma & Biotech segment is expanding its footprint for Parenteral Dosage Form development with a further build-out of its Drug Product Services (DPS).

This investment will significantly expand both capability and capacity of DPS at the Stücki Science Park in Basel (CH) and will create more than 50 new positions. The expanded offering includes new capabilities for drug product process development.

DPS opened its laboratories in November 2016 with an initial focus on Formulation Development and Drug Product Analytical Development. This facility was recently granted a GMP license after a successful audit by Swissmedic allowing QC release and stability testing of drug products.

"This significant expansion represents an important milestone in Lonza's evolution to become a fully integrated drug development partner. With the recent acquisition of Capsugel, combined with DPS's excellence in parenterals, we offer a wide range of services to meet our customers' drug product needs," said Marc Funk, COO of Lonza's Pharma & Biotech segment. "Our expansion in Basel also signals Lonza's strong commitment to the local community."

The DPS team provides a holistic approach to drug product development that anticipates and prevents problems early and helps ensure the product is optimal for manufacture, supply chain and patient use. The DPS team provides a complete portfolio of services for parenteral dosage forms including products for injection and infusion for intravenous, subcutaneous, and intraocular routes of administration.

These offerings also include specialized services, such as:

- Particulate identification, characterization and quantification
- Excipient and surfactant characterization
- Extractables and leachables assessment
- Container closure integrity testing

"The expansion of Drug Product Services reflects the value that Lonza brings to our pharma and biotech customers through exceptional experience, a strong scientific track record and state-of-the-art instrumental infrastructure which enables them to accelerate and de-risk Drug Product development and commercialization," said Prof Dr. Hanns-Christian Mahler, Lonza's Head of Drug Product Services.



Lonza Ltd Muenchensteinerstrasse 38 CH-4002 Basel, Switzerland +41 61 316 81 11 +41 61 316 91 11 media@lonza.com

Lonza

About Lonza

Following the closing of the Capsugel acquisition, Lonza further strengthened its position as one of the world's leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. Lonza harnesses science and technology to create products that support safer and healthier living and that enhance the overall quality of life.

An integrated solutions provider serving the healthcare continuum, Lonza offers products and services from the custom development and manufacturing of active pharmaceutical ingredients to innovative dosage forms for the pharma and consumer health and nutrition industries. In addition to drinking water sanitizers, nutraceuticals, antidandruff agents and other personal care ingredients, the Lonza group provides agricultural products, advanced coatings and composites and microbial control solutions that combat dangerous viruses, bacteria and other pathogens.

Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 50 major manufacturing and R&D facilities and nearly 14,000 full-time employees worldwide. Further information can be found at www.lonza.com.

Lonza Contact Details

Dirk Oehlers, Head Investor Relations
Lonza Group Ltd
Tel +41 61 316 8540
dirk.oehlers@lonza.com

Dominik Werner, Head Corporate Communications Lonza Group Ltd Tel +41 61 316 8798 dominik.werner@lonza.com

Constance Ward, Head External Communications Lonza Group Ltd Tel +41 61 316 8840 constance.ward@lonza.com

Additional Information and Disclaimer

Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited ("SGX-ST"). Lonza Group Ltd is not subject to the SGX-ST's continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.